NASDAQ:IBRX ImmunityBio (IBRX) Stock Price, News & Analysis $6.02 -0.56 (-8.45%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$6.07 +0.06 (+0.91%) As of 11/20/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ImmunityBio Stock (NASDAQ:IBRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImmunityBio alerts:Sign Up Key Stats Today's Range$6.00▼$6.5350-Day Range$5.98▼$10.5152-Week Range$1.95▼$12.43Volume10.56 million shsAverage Volume13.00 million shsMarket Capitalization$6.40 billionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingModerate Buy Company Overview ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses. The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio also has investigational treatments in development for cancer and other diseases. ImmunityBio was formed through the combination of ImmunityBio and NantKwest, completed in 2021. The company is based in California and conducts research and development and commercial activities focused on bringing its therapies to patients.AI Generated. May Contain Errors. Read More ImmunityBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreIBRX MarketRank™: 1.72676837725 of 5 starsImmunityBio scored higher than 35% of companies evaluated by MarketBeat, and ranked 642nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingImmunityBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialImmunityBio has a consensus price target of $16.00, representing about 166.0% upside from its current price of $6.02.Amount of Analyst CoverageImmunityBio has only been the subject of 4 research reports in the past 90 days.Read more about ImmunityBio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ImmunityBio are expected to decrease in the coming year, from ($0.47) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunityBio is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunityBio is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted35.09% of the float of ImmunityBio has been sold short.Short Interest Ratio / Days to CoverImmunityBio has a short interest ratio ("days to cover") of 10.77, which indicates bearish sentiment.Change versus previous monthShort interest in ImmunityBio has recently increased by 2.55%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunityBio does not currently pay a dividend.Dividend GrowthImmunityBio does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.06 News SentimentImmunityBio has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for ImmunityBio this week, compared to 9 articles on an average week.Search InterestOnly 34 people have searched for IBRX on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is a decrease of -12% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ImmunityBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,119,838.00 in company stock.Percentage Held by Insiders66.10% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions8.58% of the stock of ImmunityBio is held by institutions.Read more about ImmunityBio's insider trading history. Receive IBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBRX Stock News HeadlinesDoes ImmunityBio, Inc. (IBRX) Have More Upside on Major ANKTIVA Milestones2 hours ago | insidermonkey.comImmunityBio: Q3 ANKTIVA Slowdown And Cash Burn Reaffirm My Sell RatingNovember 20 at 9:52 AM | seekingalpha.comBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.November 21 at 1:00 AM | Banyan Hill Publishing (Ad)ImmunityBio (IBRX) Could Be 53% Undervalued As Anktiva Trial Results Lift FDA HopesNovember 19 at 12:31 AM | uk.finance.yahoo.comImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™November 19 at 9:29 AM | marketscreener.comMIBRX CEO reveals fresh Anktiva data after bladder cancer trial win — says FDA filing is just weeks awayNovember 17, 2026 | msn.comTranscript : ImmunityBio, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 10:40 AMNovember 16, 2026 | marketscreener.comMImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptNovember 16, 2026 | seekingalpha.comSee More Headlines IBRX Stock Analysis - Frequently Asked Questions How have IBRX shares performed this year? ImmunityBio's stock was trading at $1.98 at the beginning of the year. Since then, IBRX stock has increased by 203.8% and is now trading at $6.0150. How were ImmunityBio's earnings last quarter? ImmunityBio, Inc. (NASDAQ:IBRX) posted its earnings results on Tuesday, August, 4th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.14. The company earned $51.24 million during the quarter, compared to the consensus estimate of $49.70 million. When did ImmunityBio IPO? ImmunityBio (IBRX) raised $205 million in an IPO on Tuesday, July 28th 2015. The company issued 9,531,200 shares at a price of $20.00-$23.00 per share. Who are ImmunityBio's major shareholders? ImmunityBio's top institutional investors include State Street Corp (1.99%), Goldman Sachs Group Inc. (0.39%), Cetera Investment Advisers (0.11%) and First Trust Advisors LP (0.11%). Insiders that own company stock include Barry J Simon, Cheryl Cohen and Christobel Selecky. View institutional ownership trends. How do I buy shares of ImmunityBio? Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImmunityBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunityBio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Palantir Technologies (PLTR), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA) and Super Micro Computer (SMCI). Company Calendar Last Earnings8/04/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IBRX's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IBRX CIK1326110 Webimmunitybio.com Phone(844) 696-5235FaxN/AEmployees691Year Founded2014Price Target and Rating Average Price Target for ImmunityBio$16.00 High Price Target$23.00 Low Price Target$12.00 Potential Upside/Downside+166.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$351.40 million Net Margins-607.79% Pretax Margin-607.89% Return on EquityN/A Return on Assets-54.83% Debt Debt-to-Equity RatioN/A Current Ratio4.27 Quick Ratio4.27 Sales & Book Value Annual Sales$113.29 million Price / Sales56.48 Cash FlowN/A Price / Cash FlowN/A Book Value($1.08) per share Price / Book-5.57Miscellaneous Outstanding Shares1,063,830,000Free Float360,637,000Market Cap$6.40 billion OptionableOptionable Beta0.17 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:IBRX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.